283594-90-1Cc1cc(C)c(C2=C(OC(=O)CC(C)(C)C)C3(CCCC3)OC2=O)c(C)c1GOLXNESZZPUPJE-UHFFFAOYSA-NSpiromesifen is a butenolide that is but-2-en-4-olide bearing a 2,4,6-trimethylphenyl group at position 3, a 3,3-dimethylbutyryloxy group at position 4 and a spiro-fused cyclopentyl ring at position 5. It has a role as an insecticide. It is functionally related to a 1,3,5-trimethylbenzene and a 3,3-dimethylbutyric acid.
283594-90-1Pesticides
Acaricides, Insecticides
Active substance -> EU Pesticides database: Not approved
Insecticides
Pesticide (Spiromesifen) -> USDA PDB
In n-heptane 23, isopropanol 115, n-octanol 60, polyethylene glycol 22, DMSO 55, xylene, 1,2-dichloromethane, acetone, ethyl acetate, and acetonitrile all >250 (all in g/L, 20 °C)
In water, 0.13 mg/L at 20 °C
201.8 Ų [M+Na]+ [CCS Type: DT; Buffer gas: N2; Ionization: ESI+; Dataset: Pesticides]
196.08 Ų [M]+ [CCS Type: TW; Buffer gas: N2; Ionization: GC-APCI+]
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
Warning
H317 (100%): May cause an allergic skin reaction [Warning Sensitization, Skin]
P261, P271, P272, P273, P280, P302+P352, P304+P340, P317, P321, P333+P317, P362+P364, P391, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 69 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Danger
H350: May cause cancer [Danger Carcinogenicity]
Council Directive (EEC) No 414/1991 (Repealed by Reg. EC No 1107/2009 (amended))
Spiromesifen is listed in the dataset of EPA Human Health Benchmarks for Pesticides under the Safe Drinking Water Act (40 eCFR 141)
2011/252/EU, 2011/252/EU, Dossier complete 03/105/EC, Dossier complete 03/105/EC, Reg. (EU) 2018/155, Reg. (EU) 2025/1092, Reg. (EU) No 375/2013, Reg. (EU) No 375/2013
REACH registered substance: Spiromesifen (EC: 608-196-5)
Tolerances are established for residues of the insecticide/miticide spiromesifen, including its metabolites and degradates, in or on the commodities listed below. Compliance with the tolerance levels specified below is to be determined by measuring only the sum of spiromesifen [2-oxo-3-(2,4,6-trimethylphenyl)-1-oxaspiro[4.4]non-3-en-4-yl 3,3-dimethylbutanoate] and 4-hydroxy-3-(2,4,6-trimethylphenyl)-1-oxaspiro[4.4]non-3-en-2-one, calculated as the stoichiometric equivalent of spiromesifen, in or on the following primary crop commodities: [Table#7658]
Tolerances are established for residues of the insecticide/miticide spiromesifen, including its metabolites and degradates, in or on the commodities listed below. Compliance with the tolerance levels specified below is to be determined by measuring only the sum of spiromesifen [2-oxo-3-(2,4,6-trimethylphenyl)-1-oxaspiro[4.4]non-3-en-4-yl 3,3-dimethylbutanoate] and its metabolites containing the 4-hydroxy-3-(2,4,6-trimethylphenyl)-1-oxaspiro[4.4]non-3-en-2-one and 4-hydroxy-3-[4-(hydroxymethyl)-2,6-dimethylphenyl]-1-oxaspiro[4.4]non-3-en-2-one moieties, calculated as the stoichiometric equivalent of spiromesifen, in the following livestock commodities: [Table#7659]
In livestock, spiromesifen is metabolized by the loss of the dimethylbutyric acid group to yield BSN 2060-enol. Further metabolism can include hydroxylation of BSN 2060- enol to yield BSN 2060-2-hydroxymethyl or BSN 2060-4-hydroxymethyl; hydroxylation of BSN 2060-enol to yield BSN 2060-3-pentanol; oxidation of BSN 2060-3-pentanol or BSN 2060-2- or -4-hydroxymethyl to give BSN 2060-2- or -4- hydroxymethyl-3-pentanol; oxidation of BSN 2060-4-hydroxymethyl to give BSN 2060-pentanone or BSN 2060-4-aldehyde; oxidation of BSN 2060-2- or 4- hydroxymethyl-3-pentanol to give BSN 2060-hydroxy-4-carboxy; and further hydroxylation of BSN 2060-4-hydroxymethyl-3-pentanol or BSN 2060-hydroxy-4- carboxy to give BSN 2060-dihydroxy-4-carboxy.
In a metabolism study, BSN 2060 ([Dihydrofuranone-3-14C] BSN 2060, radiochemical purity: >97%, specific activity: 146.8 uCi/mg, lot no. 12513/1, non-labeled BSN 2060, purity: 99.5%, lot no. M00391) was administered to Wistar, Crl(W1)BR VAF/Plus rats orally by gavage. The study consisted of nine individual treatment protocols. In the excretion-balance portion, a preliminary study was performed in which 4 animals/sex were treated with 500 mg/kg of the test material. In 3 additional treatments, 4 animals/sex (unless otherwise noted) were treated with a single dose of 2 mg/kg, a single dose of 500 mg/kg (males only) or 14 daily unlabeled doses of 2 mg/kg each followed by a single dose of radiolabeled 2 mg/kg on the 15th day. Urine and feces were collected at specified intervals up to 72 hours post-dose. ... The test material was initially metabolized to the keto-enol by loss of the dimethylbutyric acid moiety. Both the phenyl and cyclopentyl rings were hydroxylated and the methyl groups on the phenyl ring were ultimately oxidized to a carboxylic acid. These metabolites were largely recovered in the bile and urine. The predominant moiety recovered in the feces was the unmetabolized test material. No conjugation with either glucuronic acid or sulphate was observed.
The nature of the residue in livestock commodities is adequately understood based on metabolism studies conducted with lactating goats and laying hens. Based on these studies, spiromesifen is metabolized in all RACs by the loss of the dimethylbutyric acid group to yield BSN 2060-enol. Further metabolism can include hydroxylation of BSN 2060-enol to yield BSN 2060-2-hydroxymethyl or BSN 2060-4-hydroxymethyl; hydroxylation of BSN 2060-enol to yield BSN 2060-3-pentanol; oxidation of BSN 2060-3-pentanol or BSN 2060-2- or -4-hydroxymethyl to give BSN 2060-2- or -4- hydroxymethyl-3-pentanol; oxidation of BSN 2060-4-hydroxymethyl to give BSN 2060-pentanone or BSN 2060-4-aldehyde; oxidation of BSN 2060-2- or 4- hydroxymethyl-3-pentanol to give BSN 2060-hydroxy-4-carboxy; and further Page 30 of 56 hydroxylation of BSN 2060-4-hydroxymethyl-3-pentanol or BSN 2060-hydroxy-4- carboxy to give BSN 2060-dihydroxy-4-carboxy.
Keine Reaktionsaufzeichnungen unter den aktuellen Filterkriterien.
Wird geladen…
DTXSID1034929CHEMBL2227838CHEBI:38640203.33 Ų [M+Na]+
Time-limited tolerances specified in the following table are established for residues of the insecticide/miticide spiromesifen, including its metabolites and degradates, in or on the commodities listed below. Compliance with the tolerance levels specified below is to be determined by measuring only the sum of spiromesifen [2-oxo-3-(2,4,6-trimethylphenyl)-1-oxaspiro[4.4]non-3-en-4-yl 3,3-dimethylbutanoate] and 4-hydroxy-3-(2,4,6-trimethylphenyl)-1-oxaspiro[4.4]non-3-en-2-one, calculated as the stoichiometric equivalent of spiromesifen, in or on the specified agricultural commodities, resulting from use of the pesticide pursuant to FIFRA section 18 emergency exemptions. The tolerances expire and are revoked on the date specified in the table. [Table#7660]
Tolerances are established for the inadvertent or indirect residues of the insecticide/miticide spiromesifen, including its metabolites and degradates, in or on the commodities listed below. Compliance with the tolerance levels specified below is to be determined by measuring only the sum of spiromesifen [2-oxo-3-(2,4,6-trimethylphenyl)-1-oxaspiro[4.4]non-3-en-4-yl 3,3-dimethylbutanoate], 4-hydroxy-3-(2,4,6-trimethylphenyl)-1-oxaspiro[4.4]non-3-en-2-one, and its metabolites containing the 4-hydroxy-3-[4-(hydroxymethyl)-2,6-dimethylphenyl]-1-oxaspiro[4.4]non-3-en-2-one moiety, calculated as the stoichiometric equivalent of spiromesifen, in the following rotational crop commodities: [Table#7661]
Skin Sens. 1 (100%)
Skin sensitization - Category 1B
Suitable Extinguishing Media: water spray, carbon dioxide (CO2), dry chemical. /Oberon 4 SC Insecticide/Miticide/
Fire Fighting Instructioins: Keep out of smoke. Fight fire from upwind position. Cool closed containers exposed to fire with water spray. Do not allow run-off from fire fighting to enter drains or water courses. Equipment or materials involved in pesticide fires may become contaminated. Wear self-contained breathing apparatus and protective suit. /Oberon 4 SC Insecticide/Miticide/
Oberon 4 SC Insecticide/Miticide is packaged in poly-ethylene containers. Do not allow product or containers to freeze. Store in a cool, dry place and in such a manner as to prevent cross contamination with other pesticides, fertilizers, food and feed. Store in original container and out of the reach of children, preferably in a locked storage area. /Oberon 4 SC Insecticide/Miticide/
Safe Storage of Pesticides. Always store pesticides in their original containers, complete with labels that list ingredients, directions for use, and first aid steps in case of accidental poisoning. Never store pesticides in cabinets with or near food, animal feed, or medical supplies. Do not store pesticides in places where flooding is possible or in places where they might spill or leak into wells, drains, ground water, or surface water. /Residential users/
Do not contaminate water when cleaning equipment or disposing of equipment washwater. /Oberon 4 SC Insecticide/Miticide/
ACCIDENTAL RELEASE MEASURES. Keep unauthorized people away. Isolate hazard area. Avoid contact with spilled product or contaminated surfaces. ... Take up with absorbent material (e.g. sand, diatomaceous earth or a proprietary absorbent material). Keep in suitable, closed containers for disposal. Clean contaminated floors and objects thoroughly, observing environmental regulations. ... Use personal protective equipment. Avoid breathing vapors and avoid skin contact. Do not allow material to enter streams, sewers, or other waterways. /Oberon 4 SC Insecticide/Miticide/
If a spill occurs, clean it up promptly. Don't wash it away. Instead, sprinkle the spill with sawdust, vermiculite, or kitty litter. Sweep it into a plastic garbage bag, and dispose of it as directed on the pesticide product label./Residential users/
After Applying a Pesticide, Indoors or Outdoors. To remove pesticide residues, use a bucket to rinse tools or equipment three times, including any containers or utensils that you used when mixing the pesticide. Then pour the rinsewater into the pesticide sprayer and reuse the solution by applying it according to the pesticide product label directions. After applying any pesticide wash your hands and any other parts of your body that may have come in contact with the pesticide. To prevent tracking pesticides inside, remove or rinse your boots or shoes before entering your home. Wash any clothes that have been exposed to a lot of pesticide separately from your regular wash. /Residential users/
SRP: The most favorable course of action is to use an alternative chemical product with less inherent propensity for occupational harm/injury/toxicity or environmental contamination. Recycle any unused portion of the material for its approved use or return it to the manufacturer or supplier. Ultimate disposal of the chemical must consider: the material's impact on air quality; potential migration in soil or water; effects on animal and plant life; and conformance with environmental and public health regulations.
PESTICIDE DISPOSAL. Pesticide wastes are acutely hazardous. Improper disposal of excess pesticide, spray mixture, or rinsate is a violation of Federal Law. If these wastes cannot be disposed of by use according to label instructions, contact your State Pesticide or Environmental Control Agency, or the Hazardous Waste representative at the nearest EPA Regional Office for guidance. /Oberon 4 SC Insecticide/Miticide/
CONTAINER DISPOSAL. Non-refillable container. Do not reuse or refill this container. Triple rinse or equivalent. Then offer for recycling or reconditioning or puncture and dispose of in a sanitary landfill, or by other procedures approved by state and local authorities. /Oberon 4 SC Insecticide/Miticide/
Safe Disposal of Pesticides. The best way to dispose of small amounts of excess pesticides is to use them - apply them - according to the directions on the label. If you cannot use them, ask your neighbors whether they have a similar pest control problem and can use them. If all of the remaining pesticide cannot be properly used, check with your local solid waste management authority, environmental agency, or health department to find out whether your community has a household hazardous waste collection program or a similar program for getting rid of unwanted, leftover pesticides. These authorities can also inform you of any local requirements for pesticide waste disposal. /Residential users/
Safe Disposal of Pesticides. An empty pesticide container can be as hazardous as a full one because of residues left inside. Never reuse such a container. When empty, a pesticide container should be rinsed carefully three times and the rinsewater thoroughly drained back onto the sprayer or the container previously used to mix the pesticide. Use the rinsewater as a pesticide, following label directions. Replace the cap or closure securely. Dispose of the container according to label instructions. Do not puncture or burn a pressurized container like an aerosol - it could explode. Many communities have programs to recycle household waste such as empty bottles and cans. Do not recycle any pesticide containers, however, unless the recycling program specifically accepts pesticide containers and you follow the program's instructions for preparing the empty containers for collection. /Residential users/
Use this product only in accordance with its labeling and with the Worker Protection Standard, 40 CFR part 170. /Oberon 4 SC Insecticide/Miticide/
This pesticide is toxic to fish and aquatic invertebrates. Do not contaminate surface water through spray drift. Do not apply directly to water, or to areas where surface water is present or to intertidal areas below the mean high water mark. /Oberon 4 SC Insecticide/Miticide/
Do not apply this product in a way that will contact workers or other persons, either directly or through drift. Only protected handlers may be in the same area during application. /Oberon 4 SC Insecticide/Miticide/
Do not enter or allow worker entry into treated areas during the restricted entry interval (REI) of 12 hours following application. /Oberon 4 SC Insecticide/Miticide/
For more Preventive Measures (Complete) data for Spiromesifen (13 total), please visit the HSDB record page.
Tolerances are established for residues of the insecticide/miticide spiromesifen, including its metabolites and degradates, in or on the commodities listed below. Compliance with the tolerance levels specified below is to be determined by measuring only the sum of spiromesifen [2-oxo-3-(2,4,6-trimethylphenyl)-1-oxaspiro[4.4]non-3-en-4-yl 3,3-dimethylbutanoate] and 4-hydroxy-3-(2,4,6-trimethylphenyl)-1-oxaspiro[4.4]non-3-en-2-one, calculated as the stoichiometric equivalent of spiromesifen, in or on the following primary crop commodities: [Table#7654]
Tolerances are established for residues of the insecticide/miticide spiromesifen, including its metabolites and degradates, in or on the commodities listed below. Compliance with the tolerance levels specified below is to be determined by measuring only the sum of spiromesifen [2-oxo-3-(2,4,6-trimethylphenyl)-1-oxaspiro[4.4]non-3-en-4-yl 3,3-dimethylbutanoate] and its metabolites containing the 4-hydroxy-3-(2,4,6-trimethylphenyl)-1-oxaspiro[4.4]non-3-en-2-one and 4-hydroxy-3-[4-(hydroxymethyl)-2,6-dimethylphenyl]-1-oxaspiro[4.4]non-3-en-2-one moieties, calculated as the stoichiometric equivalent of spiromesifen, in the following livestock commodities: [Table#7655]
Time-limited tolerances specified in the following table are established for residues of the insecticide/miticide spiromesifen, including its metabolites and degradates, in or on the commodities listed below. Compliance with the tolerance levels specified below is to be determined by measuring only the sum of spiromesifen [2-oxo-3-(2,4,6-trimethylphenyl)-1-oxaspiro[4.4]non-3-en-4-yl 3,3-dimethylbutanoate] and 4-hydroxy-3-(2,4,6-trimethylphenyl)-1-oxaspiro[4.4]non-3-en-2-one, calculated as the stoichiometric equivalent of spiromesifen, in or on the specified agricultural commodities, resulting from use of the pesticide pursuant to FIFRA section 18 emergency exemptions. The tolerances expire and are revoked on the date specified in the table. [Table#7656]
Tolerances are established for the inadvertent or indirect residues of the insecticide/miticide spiromesifen, including its metabolites and degradates, in or on the commodities listed below. Compliance with the tolerance levels specified below is to be determined by measuring only the sum of spiromesifen [2-oxo-3-(2,4,6-trimethylphenyl)-1-oxaspiro[4.4]non-3-en-4-yl 3,3-dimethylbutanoate], 4-hydroxy-3-(2,4,6-trimethylphenyl)-1-oxaspiro[4.4]non-3-en-2-one, and its metabolites containing the 4-hydroxy-3-[4-(hydroxymethyl)-2,6-dimethylphenyl]-1-oxaspiro[4.4]non-3-en-2-one moiety, calculated as the stoichiometric equivalent of spiromesifen, in the following rotational crop commodities: [Table#7657]
Mixers, loaders and other handlers must wear: Long-sleeved shirt and long pants, chemical resistant gloves (such as natural rubber, selection category A), and shoes plus socks. /Oberon 4 SC Insecticide/Miticide/
Applicators must wear: Long-sleeved shirt and long pants and shoes plus socks. /Oberon 4 SC Insecticide/Miticide/
... Restricted entry interval (REI) of 12 hours following application. PPE required for early entry to treated areas that is permitted under the Worker Protection Standard and that involves contact with anything that has been treated such as plants, soil or water, are: Coveralls over short sleeved shirt and short pants. Chemical resistant gloves (such as natural rubber, selection category A). Shoes plus socks. /Oberon 4 SC Insecticide/Miticide/
When handlers use closed systems or enclosed cabs in a manner that meets the requirements listed in the Worker Protection Standard (WPS) for agricultural pesticides [40 CFR 170.240 (d)(4-6)], the handler PPE requirements may be reduced or modified as specified in the WPS. /Oberon 4 SC Insecticide/Miticide/
TERRESTRIAL FATE: Based on a classification scheme(1), an estimated Koc value of 34,000(SRC), determined from a structure estimation method(2), indicates that spiromesifen is expected to be immobile in soil(SRC). Volatilization of spiromesifen from moist soil surfaces is expected to be an important fate process(SRC) given an estimated Henry's Law constant of 5.6X10-4 atm-cu m/mole(SRC), based upon its vapor pressure, 1.5X10-4 mm Hg(3), and water solubility, 0.13 mg/L(3). However, adsorption to soil is expected to attenuate volatilization(SRC). Spiromesifen is not expected to volatilize from dry soil surfaces(SRC) based upon its vapor pressure(3). Soil biodegradation half-lives of spiromesifen have been reported as 2.6 to 17.9 days(3).
AQUATIC FATE: Based on a classification scheme(1), an estimated Koc value of 34,000(SRC), determined from a structure estimation method(2), indicates that spiromesifen is expected to adsorb to suspended solids and sediment(SRC). Volatilization from water surfaces is expected(3) based upon an estimated Henry's Law constant of 5.6X10-4 atm-cu m/mole(SRC), derived from its vapor pressure, 1.5X10-4 mm Hg(4), and water solubility, 0.13 mg/L(4). Using this Henry's Law constant and an estimation method(3), volatilization half-lives for a model river and model lake are 8.6 hours and 8.5 days, respectively(SRC). However, volatilization from water surfaces is expected to be attenuated by adsorption to suspended solids and sediment in the water column. The estimated volatilization half-life from a model pond is 206 days if adsorption is considered(5). According to a classification scheme(6), an estimated BCF of 470(SRC), from its log Kow of 4.55(7) and a regression-derived equation(8), suggests the potential for bioconcentration in aquatic organisms is high(SRC). Spiromesifen hydrolysis half-lives are reported as 53.3, 24.8 and 4.3 days at pH 4, 7 and 9, respectively(4). Biodegradation of spiromesifen may take place in aquatic environments based on reported half-lives in soil of 2.6 to 17.9 days(4).
ATMOSPHERIC FATE: According to a model of gas/particle partitioning of semivolatile organic compounds in the atmosphere(1), spiromesifen, which has a vapor pressure of 1.5X10-4 mm Hg at 20 °C(2), is expected to exist solely as a vapor in the ambient atmosphere. Vapor-phase spiromesifen is degraded in the atmosphere by reaction with photochemically-produced hydroxyl radicals(SRC); the half-life for this reaction in air is estimated to be 5 hours(SRC), calculated from its rate constant of 7.6X10-11 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(3). Vapor-phase spiromesifen is also degraded in the atmosphere by reaction with ozone(SRC); the half-life for this reaction in air is estimated to be 13 hours(SRC), calculated from its rate constant of 2.1X10-17 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(3). Spiromesifen contains chromophores that absorb at wavelengths >290 nm(4) and therefore may be susceptible to direct photolysis by sunlight(SRC).
Spiromesifen in/on unprocessed green tea (Camellia sinesis (L) O'Kuntze) leaf samples after foliar application. Plants were located at the Tea Experimental Farm, Dept of Tea Husbandry and Technology, CSK Himachal Pradesh Krishi Vishvavidyalaya Palampur (Himachal Pradesh), India(1).
The average processed tea consumption by a person in a day is 25 g, the theoretical maximum daily intake of spiromesifen is calculated as 0.099 mg/person/day, based on 3 year trials of pesticide residue, from tea harvested 3 days after dosage of 150 g/ha(1). At a dosage of 300 g/ha of spiromesifen on tea leaves the theoretical maximum daily intake increases to 0.158 mg/person/day(1).
Using a structure estimation method based on molecular connectivity indices(1), the Koc of spiromesifen can be estimated to be 34,000(SRC). According to a classification scheme(2), this estimated Koc value suggests that spiromesifen is expected to be immobile in soil.
An estimated BCF of 470 was calculated in fish for spiromesifen(SRC), using a log Kow of 4.55(1) and a regression-derived equation(2). According to a classification scheme(3), this BCF suggests the potential for bioconcentration in aquatic organisms is high(SRC).
The Henry's Law constant for spiromesifen is estimated as 5.6X10-4 atm-cu m/mole(SRC) derived from its vapor pressure, 1.5X10-5 mm Hg(1), and water solubility, 0.13 mg/L(1). This Henry's Law constant indicates that spiromesifen is expected to volatilize from water surfaces(2). Based on this Henry's Law constant, the volatilization half-life from a model river (1 m deep, flowing 1 m/sec, wind velocity of 3 m/sec)(2) is estimated as 8.6 hours(SRC). The volatilization half-life from a model lake (1 m deep, flowing 0.05 m/sec, wind velocity of 0.5 m/sec)(2) is estimated as 8.5 days(SRC). However, volatilization from water surfaces is expected to be attenuated by adsorption to suspended solids and sediment in the water column(SRC). The estimated volatilization half-life from a model pond is 206 days if adsorption is considered(3). Spiromesifen's estimated Henry's Law constant indicates that volatilization from moist soil surfaces may occur(SRC). Spiromesifen is not expected to volatilize from dry soil surfaces(SRC) based upon its vapor pressure(1).
/LABORATORY ANIMALS: Acute Exposure/ Study type: Skin sensitization - guinea pig; Results: Potential moderate contact sensitizer. /From table/c
/LABORATORY ANIMALS: Acute Exposure/ Spiromesifen is believed to exert its effects through the inhibition of lipid biosynthesis. The critical effects observed are loss of body weight, adrenal effects (discoloration, decrease in fine vesiculation, and the presence of cytoplasmic eosinophilia in zona fasciculata cells), thyroid effects (increased thyroid-stimulating hormone, increased thyroxine binding capacity, decreased T3 and T4 levels, colloidal alteration and thyroid follicular-cell hypertrophy), liver effects (increased alkaline phosphatase, ALT and decreased cholesterol, triglycerides), and spleen effects (atrophy, decreased spleen-cell count, and increased macrophages).
/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ In a 90-day oral toxicity study, BSN 2060 Technical (/spiromesifen/ purity: 97.6%) was administered to 4 beagle dogs/sex/dose in the diet at dose levels of 0, 3000 or 5000 ppm (equivalent to 0, 98.4, 172.5 mg/kg bw/day for males and 0, 102.8, 170.8 mg/kg bw/day for females) for 13 weeks. There were no treatment-related effects on the mean body weights, body weight gain, food consumption or the various physiological parameters which were evaluated (reflexes, body temperature, blood pressure, heart rate, and electrocardiogram). Ophthalmoscopy, hematology and urinalysis did not indicate any treatment-related effects. In the clinico-chemical evaluation, the alanine aminotransferase and alkaline phosphatase activities were elevated for both sexes in both treatment groups. The liver enzymes, N- and O-demethylase, Cytochrome P450, 7-ethoxycoumarin deethylase, aldrin epoxidase, and epoxide hydrolase had elevated activity levels for both of the treatment groups. There was an increase in both the mean absolute and mean relative liver weights for both treatment groups. In the histopathological examination, predominantly moderate hepatocellular hypertrophy, cytoplasmic change and a minimal to slight increase in lipid content was noted for animals in both of the treatment groups. Minimal to slight hepatocellular degeneration was observed in one animal of both treatment groups. A minimal to slightly increased cortical vacuolation in the adrenal glands was observed in one animal in both treatment groups. Although serum thyroxine levels were decreased for the treated animals throughout the study, there were no other effects which directly indicated thyroid toxicity. The mean absolute and relative thyroid weights were not affected in a treatment-related manner. There was no treatment-related histopathology in the thyroid and the other thyroid-related clinical parameters (triiodothyronine, thyroxine-binding index, thyroxine-stimulating hormone) were not apparently affected by the treatment. Histopathological examination of the epididymides of the males in the two treated groups revealed an increased incidence of cellular debris (4 of 8 animals) and oligospermia in one animal of the 5000 ppm group. The mean absolute and relative epididymal weights were lower in a dose-related manner. The study authors attributed these results to the sexual immaturity of the test animals even though the controls animals did not demonstrate similar effects. The increasing concentration of the metabolite in the plasma indicated an extended half life for the parent compound. The target organ was the liver. These study data were not adequate to establish a LOAEL or a NOAEL.
The rate constant for the vapor-phase reaction of spiromesifen with photochemically-produced hydroxyl radicals has been estimated as 7.6X10-11 cu cm/molecule-sec at 25 °C(SRC) using a structure estimation method(1). This corresponds to an atmospheric half-life of about 5 hours at an atmospheric concentration of 5X10+5 hydroxyl radicals per cu cm(1). The rate constant for the vapor-phase reaction of spiromesifen with ozone has been estimated as 2.1X10-17 cu cm/molecule-sec at 25 °C(SRC) that was derived using a structure estimation method(1). This corresponds to an atmospheric half-life of about 13 hours at an atmospheric concentration of 7X10+11 ozone molecules per cu cm(2). Spiromesifen hydrolysis half-lives are reported as 53.3, 24.8 and 4.3 days at pH 4, 7 and 9, respectively(3). Spiromesifen contains chromophores that absorb at wavelengths >290 nm(4) and therefore may be susceptible to direct photolysis by sunlight(SRC).
Occupational exposure to spiromesifen may occur through inhalation and dermal contact with this compound at workplaces where spiromesifen is produced or used. Monitoring and use data indicate that the general population may be exposed to spiromesifen via ingestion of food treated with spiromesifen. (SRC).
Tolerances are established for residues of the insecticide/miticide spiromesifen, including its metabolites and degradates, in or on the commodities listed below. Compliance with the tolerance levels specified below is to be determined by measuring only the sum of spiromesifen [2-oxo-3-(2,4,6-trimethylphenyl)-1-oxaspiro[4.4]non-3-en-4-yl 3,3-dimethylbutanoate] and 4-hydroxy-3-(2,4,6-trimethylphenyl)-1-oxaspiro[4.4]non-3-en-2-one, calculated as the stoichiometric equivalent of spiromesifen, in or on the following primary crop commodities: [Table#7658]
Tolerances are established for residues of the insecticide/miticide spiromesifen, including its metabolites and degradates, in or on the commodities listed below. Compliance with the tolerance levels specified below is to be determined by measuring only the sum of spiromesifen [2-oxo-3-(2,4,6-trimethylphenyl)-1-oxaspiro[4.4]non-3-en-4-yl 3,3-dimethylbutanoate] and its metabolites containing the 4-hydroxy-3-(2,4,6-trimethylphenyl)-1-oxaspiro[4.4]non-3-en-2-one and 4-hydroxy-3-[4-(hydroxymethyl)-2,6-dimethylphenyl]-1-oxaspiro[4.4]non-3-en-2-one moieties, calculated as the stoichiometric equivalent of spiromesifen, in the following livestock commodities: [Table#7659]
Time-limited tolerances specified in the following table are established for residues of the insecticide/miticide spiromesifen, including its metabolites and degradates, in or on the commodities listed below. Compliance with the tolerance levels specified below is to be determined by measuring only the sum of spiromesifen [2-oxo-3-(2,4,6-trimethylphenyl)-1-oxaspiro[4.4]non-3-en-4-yl 3,3-dimethylbutanoate] and 4-hydroxy-3-(2,4,6-trimethylphenyl)-1-oxaspiro[4.4]non-3-en-2-one, calculated as the stoichiometric equivalent of spiromesifen, in or on the specified agricultural commodities, resulting from use of the pesticide pursuant to FIFRA section 18 emergency exemptions. The tolerances expire and are revoked on the date specified in the table. [Table#7660]
Tolerances are established for the inadvertent or indirect residues of the insecticide/miticide spiromesifen, including its metabolites and degradates, in or on the commodities listed below. Compliance with the tolerance levels specified below is to be determined by measuring only the sum of spiromesifen [2-oxo-3-(2,4,6-trimethylphenyl)-1-oxaspiro[4.4]non-3-en-4-yl 3,3-dimethylbutanoate], 4-hydroxy-3-(2,4,6-trimethylphenyl)-1-oxaspiro[4.4]non-3-en-2-one, and its metabolites containing the 4-hydroxy-3-[4-(hydroxymethyl)-2,6-dimethylphenyl]-1-oxaspiro[4.4]non-3-en-2-one moiety, calculated as the stoichiometric equivalent of spiromesifen, in the following rotational crop commodities: [Table#7661]
In a metabolism study, BSN 2060-Phenyl- UL-14C (batch no. not provided, radiochemical purity: 100%, specific activity: 34.9 mCi/mmol) was administered intravenously to one male rhesus monkey at a dose level of 0.231 mg/kg (21.8 uCi/kg). In a second part of the study, BSN 2060 SC480 (batch no. K1 BRD (0037), ai 45.2%) containing BSN 2060-Phenyl-UL-14C, was applied to the skin of one male rhesus monkey at a dose of 0.191 mg/kg or 18.3 ug/sq cm (18.0 uCi/kg) for eight hours. Dosing via the intravenous route resulted in the excretion of the radiolabel largely in the urine. The percentage of the administered dose which was recovered in the urine, feces and cage debris/rinse samples was as follows: urine (54.32%), feces (13.08%), and cage debris/rinse (26.57%). A significant fraction of the dose was recovered in the cage debris/rinse. Although it was not definitive whether this radiolabel was from the urine or feces, a greater part of that fraction was recovered prior to any radiolabel being found in the feces. The 13% of the dose which was definitively recovered in the feces had likely passed through the biliary excretion route. Excretion was relatively rapid with greater than 70% of the administered dose recovered within the first 24 hours. Dermal application of the test material resulted in only limited absorption for the eight-hour exposure period, 3.31%. A large fraction of that total was recovered from the urine and cage debris/rinse showing that it is poorly absorbed through the skin layers.
In a metabolism study, BSN 2060 ([Dihydrofuranone-3-14C] BSN 2060, radiochemical purity: >97%, specific activity: 146.8 uCi/mg, lot no. 12513/1, non-labeled BSN 2060, purity: 99.5%, lot no. M00391) was administered to Wistar, Crl(W1)BR VAF/Plus rats orally by gavage. The study consisted of nine individual treatment protocols. In the excretion-balance portion, a preliminary study was performed in which 4 animals/sex were treated with 500 mg/kg of the test material. In 3 additional treatments, 4 animals/sex (unless otherwise noted) were treated with a single dose of 2 mg/kg, a single dose of 500 mg/kg (males only) or 14 daily unlabeled doses of 2 mg/kg each followed by a single dose of radiolabeled 2 mg/kg on the 15th day. Urine and feces were collected at specified intervals up to 72 hours post-dose. In the preliminary test, expired air was collected as well for the same time interval. In the 3 blood/plasma pharmacokinetics protocols, 12 animals/sex (unless otherwise noted) were dosed with a single dose of 2 mg/kg, a single dose of 500 mg/kg (males only) or 14 daily unlabeled doses of 2 mg/kg each followed by a single dose of radiolabeled 2 mg/kg on the 15th day. Blood was collected from 4 animals/sex at specified time points up to 120 hours post-dose. In the biliary excretion study, 4 males whose bile ducts had been cannulated received a single dose of 2 mg/kg and bile, urine and feces were collected at specified time points up to 48 hours post-dose. In the whole body autoradiography study, 6 males received a single dose of 2 mg/kg and one animal was euthanized at each specified time point up to 72 hours post-dose. For a single dose of 2 mg/kg, 39% of the administered dose was excreted in the urine and 55 to 57% in the feces with 88 to 90% of the dose being eliminated within the first 24 hours. Treatment with multiple doses of 2 mg/kg did not affect the ratio of radiolabel excreted in the urine and feces. Concentrations of residual radioactivity in the tissues were quite low at 72 hours post-dose. Treatment with 500 mg/kg of the test material resulted in a much lower percentage of the administered dose being excreted in the urine (7 to 9%) with the remainder recovered in the feces. Following a single dose of 2 mg/kg, the test material was rapidly if incompletely absorbed with the Cmax value in the blood achieved within 1 to 2 hours post-dose. Treatment with multiple doses of 2 mg/kg or a single dose of 500 mg/kg delayed the Tmax to 3 to 4 hours and 6 hours, respectively. The Cmax values and the concentration versus time curves [AUC(t)] indicated a disproportionately lower increase in the uptake of the radiolabel into the blood between the 2 mg/kg and 500 mg/kg treatments. At 500 mg/mg, these values were approximately 80% less than would be predicted by a proportionately linear increase. These data confirmed the reduced percentage of radiolabel which was absorbed at the 500 mg/kg treatment level in the excretion-balance profile. In the two 2 mg/kg treatment regimens, the Cmax and AUC(t) values for the females were less than those of the males with values ranging from 66 to 86% for Cmax and 43 to 55% for AUC(t) in comparison to the males. These data indicated that the females experienced less of an exposure to the test material than did the males. The whole-body autoradiograms qualitatively demonstrated the distribution of the radioactivity throughout the body. The highest areas of concentration at 1 hour post-dose were the gastrointestinal tract, bladder and blood within the heart. Overall tissue distribution appeared to be the highest at 4 hours post-dose with a progressive diminishment over the time-course of the study. At 48 hours post-dose, observable levels of radioactivity were present only in the gastrointestinal tract, kidneys and bladder. The test material was initially metabolized to the keto-enol by loss of the dimethylbutyric acid moiety. Both the phenyl and cyclopentyl rings were hydroxylated and the methyl groups on the phenyl ring were ultimately oxidized to a carboxylic acid. These metabolites were largely recovered in the bile and urine. The predominant moiety recovered in the feces was the unmetabolized test material. No conjugation with either glucuronic acid or sulfate was observed.
Insecticides (tetronic acid insecticides)
For spiromesifen (USEPA/OPP Pesticide Code: 024875) ACTIVE products with label matches. /SRP: Registered for use in the U.S. but approved pesticide uses may change periodically and so federal, state and local authorities must be consulted for currently approved uses./
Insecticide
For use on cotton, field corn, ornamentals, pome fruit, strawberries, and vegetables
Suspension concentrate (= flowable concentrate)
Forbid 4F Ornamental Insecticide/Miticide (Bayer Environmental Science) 45.2% Spiromesifen
Oberon 4 SC Insecticide/Miticide (Bayer Cropscience LP.) 45.2% Spiromesifen
Oberon 2SC Insecticide/Miticide (Bayer Cropscience LP.) 23.1% Spiromesifen
For more Formulations/Preparations (Complete) data for Spiromesifen (6 total), please visit the HSDB record page.
VerwendenInsecticide.
DefinitionChEBI: A butenolide that is but-2-en-4-olide bearing a 2,4,6-trimethylphenyl group at position 3, a 3,3-dimethylbutyryloxy group at position 4 and a spiro-fused cyclopentyl ring at position 5.
/LABORATORY ANIMALS: Subchronic or Prechronic Exposure/ In a 90-day oral toxicity study. Spiromesifen (97.4% purity) was administered to four beagle dogs/sex/dose in diet at dose levels of 0, 20, 50, 250, or 2000 ppm (equivalent to 0, 0.75, 1.85, 9.2, or 71 mg/kg bw/day). Treatment throughout the dosage range tested was well tolerated: there were no effects on clinical signs, body weight, food consumption, reflexes, EKG's, or ophthalmology. Marked, dose-related increases in liver metabolic enzyme activities were noted at 250 and 2000 ppm for activities of aminopyrine-N-demethylase (about 2-fold and 4-fold, respectively) and p-nitroanisole-O-demethylase (about 1.5-fold and 2-fold, respectively), and for 7-ethoxycoumarin deethylation activity (about 3-fold and 4- to 6-fold, respectively). Epoxide hydrolase activity in homogenized liver was marginally increased at 250 ppm (34% increase in males, 86% in females) and substantially increased (over 2-fold) at 2000 ppm. Cytochrome P-450 levels were elevated in 250 ppm females (33%) and at 2000 ppm in both sexes (2-fold). These findings are consistent with enhanced liver metabolic capacity, and with liver cytoplasmic change (centrilobular hepatocytes had cytoplasm considered 'more homogeneous and dense' than control tissue). This was the only histopathology clearly attributable to treatment in this study. Incidences were 0, 0, 0, 3, and 3 in controls through increasing dose groups in males, and 0, 0, 0, 2, and 2 in corresponding females (N = 4 in all cases). Thyroxine (T4) levels in 250 ppm females were reduced by an average of 33% during the treatment phase. There was no gender difference in T4 levels in 2000 ppm dogs, which averaged a 63% reduction during treatment compared to controls. These changes were plausibly due to increased liver metabolism. All other effects were observed only in 2000 ppm dogs. These included absolute liver weight increases of 15% and 21% in males and females, respectively, as well as elevated plasma alkaline phosphatase activity (average 3-fold increase) and a minor increase in gamma-glutamyl transferase (GGT) activity, both of which enzyme changes are associated with cholestasis, which could result from hepatocellular hypertrophy. Additional findings at 2000 ppm were elevated liver levels of triglycerides (about 80% increase), plus about 2-fold increased levels of metabolic enzyme activities in liver tissue for aldrin epoxide and UDP-glucuronyl transferase. In a brief elective metabolic disposition assay, assessment of plasma samples taken 22 hr after dosing during week 12 revealed no detectable parent compound, but BSN 546 (the enol product of ester bond cleavage) was quantifiable at 250 and 2000 ppm. In that range, detected levels rose only about 3-fold for an 8-fold difference in administered dose. Mean plasma concentrations in 2000 ppm males and females were 31 and 41 nmol/mL, respectively. The LOAEL of 250 ppm and associated NOAEL of 50 ppm (respectively equivalent to 9.2 mg/kg/day and 1.85 mg/kg/day: no notable sex differences) were based upon the above effects, which indicated liver as the primary target organ. The 4-week pilot study by the same investigators (MRID 45854506) evaluated effectively the same set of parameters, and is briefly reviewed as an appendix to this 90-day study. The 4-week study found liver metabolic activity toward several substrates at 100 ppm (3.8 mg/kg/day) but not at the next lower dose of 25 ppm (0.92 mg/kg/day), suggesting that the NOAEL for the subchronic study was close to a level eliciting a measurable response.
For more Non-Human Toxicity Excerpts (Complete) data for Spiromesifen (28 total), please visit the HSDB record page.